Inoviq Ltd - Asset Resilience Ratio
Inoviq Ltd (IIQ) has an Asset Resilience Ratio of 56.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IIQ working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2025)
This chart shows how Inoviq Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Inoviq Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Inoviq Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Inoviq Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$13.80 Million | 56.29% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$13.80 Million | 56.29% |
Asset Resilience Insights
- Very High Liquidity: Inoviq Ltd maintains exceptional liquid asset reserves at 56.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Inoviq Ltd Industry Peers by Asset Resilience Ratio
Compare Inoviq Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Inoviq Ltd (1993–2025)
The table below shows the annual Asset Resilience Ratio data for Inoviq Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 35.33% | AU$6.52 Million ≈ $4.61 Million |
AU$18.46 Million ≈ $13.06 Million |
-7.21pp |
| 2024-06-30 | 42.54% | AU$9.23 Million ≈ $6.53 Million |
AU$21.71 Million ≈ $15.36 Million |
+6.22pp |
| 2023-06-30 | 36.32% | AU$7.81 Million ≈ $5.53 Million |
AU$21.51 Million ≈ $15.22 Million |
-13.69pp |
| 2022-06-30 | 50.02% | AU$15.39 Million ≈ $10.89 Million |
AU$30.78 Million ≈ $21.78 Million |
+35.11pp |
| 2021-06-30 | 14.91% | AU$5.00 Million ≈ $3.54 Million |
AU$33.52 Million ≈ $23.72 Million |
-84.45pp |
| 2020-06-30 | 99.36% | AU$7.33 Million ≈ $5.18 Million |
AU$7.37 Million ≈ $5.22 Million |
+0.27pp |
| 2019-06-30 | 99.08% | AU$7.56 Million ≈ $5.35 Million |
AU$7.63 Million ≈ $5.40 Million |
-0.40pp |
| 2018-06-30 | 99.49% | AU$1.45 Million ≈ $1.02 Million |
AU$1.45 Million ≈ $1.03 Million |
+98.71pp |
| 2016-06-30 | 0.78% | AU$25.65K ≈ $18.15K |
AU$3.29 Million ≈ $2.33 Million |
+0.58pp |
| 2015-06-30 | 0.20% | AU$3.62K ≈ $2.56K |
AU$1.85 Million ≈ $1.31 Million |
+0.06pp |
| 2014-06-30 | 0.14% | AU$3.89K ≈ $2.75K |
AU$2.82 Million ≈ $2.00 Million |
-2.98pp |
| 2013-06-30 | 3.12% | AU$131.65K ≈ $93.15K |
AU$4.23 Million ≈ $2.99 Million |
+2.06pp |
| 2012-06-30 | 1.06% | AU$172.15K ≈ $121.80K |
AU$16.29 Million ≈ $11.53 Million |
-1.97pp |
| 2011-06-30 | 3.02% | AU$811.50K ≈ $574.19K |
AU$26.85 Million ≈ $19.00 Million |
+1.19pp |
| 2010-06-30 | 1.83% | AU$358.99K ≈ $254.01K |
AU$19.60 Million ≈ $13.87 Million |
-0.56pp |
| 2009-06-30 | 2.39% | AU$477.55K ≈ $337.90K |
AU$19.96 Million ≈ $14.13 Million |
-9.46pp |
| 2008-06-30 | 11.86% | AU$727.10K ≈ $514.47K |
AU$6.13 Million ≈ $4.34 Million |
+11.84pp |
| 2005-06-30 | 0.02% | AU$2.63K ≈ $1.86K |
AU$17.44 Million ≈ $12.34 Million |
-0.16pp |
| 2004-06-30 | 0.17% | AU$6.10K ≈ $4.32K |
AU$3.50 Million ≈ $2.48 Million |
-4.28pp |
| 2003-06-30 | 4.46% | AU$118.68K ≈ $83.98K |
AU$2.66 Million ≈ $1.88 Million |
-17.54pp |
| 2002-06-30 | 22.00% | AU$631.88K ≈ $447.09K |
AU$2.87 Million ≈ $2.03 Million |
+21.77pp |
| 1999-06-30 | 0.23% | AU$21.66K ≈ $15.33K |
AU$9.47 Million ≈ $6.70 Million |
+0.14pp |
| 1998-06-30 | 0.08% | AU$9.80K ≈ $6.93K |
AU$11.57 Million ≈ $8.18 Million |
-1.27pp |
| 1997-06-30 | 1.36% | AU$153.49K ≈ $108.60K |
AU$11.33 Million ≈ $8.01 Million |
-4.67pp |
| 1996-06-30 | 6.02% | AU$688.76K ≈ $487.34K |
AU$11.44 Million ≈ $8.09 Million |
+0.40pp |
| 1995-06-30 | 5.62% | AU$591.00K ≈ $418.17K |
AU$10.51 Million ≈ $7.44 Million |
-0.48pp |
| 1994-06-30 | 6.10% | AU$641.00K ≈ $453.55K |
AU$10.50 Million ≈ $7.43 Million |
-8.68pp |
| 1993-06-30 | 14.79% | AU$346.00K ≈ $244.82K |
AU$2.34 Million ≈ $1.66 Million |
-- |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more